The Akt Inhibitor ISC-4 Synergizes with Cetuximab in 5-FU-Resistant Colon Cancer

The Akt Inhibitor ISC-4 Synergizes with Cetuximab in 5-FU-Resistant Colon Cancer

Phenylbutyl isoselenocyanate (ISC-4) is an Akt inhibitor with demonstrated preclinical efficacy against melanoma and colon cancer. In this study, we sought to improve the clinical utility of ISC-4 by identifying a synergistic combination with FDA-approved anti-cancer therapies, a relevant and approp...

Full description

Bibliographic Details
Main Authors: Allen, Joshua E., Gallant, Jean-Nicolas, Dicker, David T., Amin, Shantu, Irby, Rosalyn B., Sharma, Arun K., El-Deiry, Wafik S.
Format: Online
Language:English
Published: Public Library of Science 2013
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3595267/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3595267/

Similar Items